PT - JOURNAL ARTICLE AU - Matov, Alexandre AU - Modiri, Shayan TI - Quantitative Microscopy in Medicine AID - 10.1101/2024.07.31.24311304 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.31.24311304 4099 - http://medrxiv.org/content/early/2024/08/03/2024.07.31.24311304.short 4100 - http://medrxiv.org/content/early/2024/08/03/2024.07.31.24311304.full AB - Methods for personalizing medical treatment are the focal point of contemporary biomedical research. In cancer care, we can analyze the effects of therapies at the level of individual cells. Quantitative characterization of treatment efficacy and evaluation of why some individuals respond to specific regimens, whereas others do not, requires additional approaches to genetic sequencing at single time points. Methods for the analysis of changes in phenotype, such as in vivo and ex vivo morphology and localization of cellular proteins and organelles can provide important insights into patient treatment options.Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface glycoprotein that is commonly overexpressed by prostate cancer (PC) cells relative to normal prostate cells, provides a validated target.We developed a software for image analysis designed to identify PSMA expression on the surface of epithelial cells in order to extract prognostic metrics. In addition, our software can deliver predictive information and inform clinicians regarding the efficacy of PC therapy. We can envisage additional applications of our software system, beyond PC, as PSMA is expressed in a variety of tissues. Our method is based on image denoising, topologic partitioning, and edge detection. These three steps allow to segment the area of each PSMA spot in an image of a coverslip with epithelial cells.Our objective has been to present the community with an integrated, easy to use by all, tool for resolving the complex cytoskeletal organization and it is our goal to have such software system approved for use in the clinical practice.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.researchgate.net/publication/374544332_Automated_Enumeration_and_Analysis_of_Circulating_Tumor_Cells_from_Peripheral_Blood_of_Metastatic_Cancer_Patients_for_Diagnosis_and_Refinement_of_Therapy_2012-2015 Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB protocols 0804009740 at Cornell Medicine.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://github.com/amatov/SegmentationBiomarkerCTC